ライフサイエンスコーパス: latent tuberculosis

1 obacteria that are thought to play a role in latent tuberculosis.

2 culosis than HIV-uninfected individuals with latent tuberculosis.

3 role in the establishment and maintenance of latent tuberculosis.

4 osis compared with ongoing treatment or with latent tuberculosis.

5 treatment, and compared to individuals with latent tuberculosis.

6 response in PBMCs of persons with active or latent tuberculosis.

7 , and accurate prediction of reactivation of latent tuberculosis.

8 vaccine and the detection/treatment rate of latent tuberculosis.

9 nterfere with the detection and treatment of latent tuberculosis.

10 t infection that provides insight into human latent tuberculosis.

11 tween vaccination and detection/treatment of latent tuberculosis.

12 nhance eradication of persistent bacilli and latent tuberculosis.

13 e that resembles the dormant state seen with latent tuberculosis.

14 markers to distinguish BCG vaccination from latent tuberculosis.

15 nflammatory diseases, is the reactivation of latent tuberculosis.

16 emotherapeutic targets for active as well as latent tuberculosis.

17 potential for identifying vaccines targeting latent tuberculosis.

18 ntensive efforts to ensure full treatment of latent tuberculosis.

19 berculosis replication rates in persons with latent tuberculosis.

20 Isoniazid is an efficacious treatment for latent tuberculosis.

21 infection or reinfection of individuals with latent tuberculosis.

22 in Phase III efficacy trials of treatment of latent tuberculosis.

23 preventing reactivation in a murine model of latent tuberculosis.

24 ation and contributing to the development of latent tuberculosis.

25 of stable granuloma, hallmark structures of latent tuberculosis.

26 ed the high impact of detecting and treating latent tuberculosis.

27 oring the safety of rifampin monotherapy for latent tuberculosis.

28 fection compromises CD8+ T-cell functions in latent tuberculosis.

29 he ROC curve (AUC) 0.90 [95% CI 0.85-0.95]), latent tuberculosis (0.88 [0.84-0.92]), and other diseas

30 practices also had increases in diagnosis of latent tuberculosis (11/59 [19%] vs 5/68 [9%], OR 3.00,

31 The most common diagnoses were latent tuberculosis (22%), viral hepatitis (17%), active

32 pregnant and postpartum women for active and latent tuberculosis; (4) the management of active and la

33 ll pose serious challenges for management of latent tuberculosis-a cornerstone of tuberculosis elimin

34 It seems likely that clinically defined latent tuberculosis actually represents a spectrum that

35 including 29 (1.15%) patients with untreated latent tuberculosis after 89 person-years of follow-up (

36 rculosis and 47.2% (95% CI, 30.0%-61.4%) for latent tuberculosis, although there was significant stat

37 Although guidelines on the management of latent tuberculosis and active tuberculosis are availabl

38 We aimed to assess the prevalence of latent tuberculosis and its associated risk factors in r

39 ment of infectious diseases such as presumed latent tuberculosis and presumed latent syphilis.

40 ment of infectious diseases such as presumed latent tuberculosis and presumed latent syphilis.

41 2% of the US population is estimated to have latent tuberculosis and there are only 11,000 cases annu

42 n derivative-negative controls, persons with latent tuberculosis, and BCG-vaccinated individuals.

43 been a considerable barrier to understanding latent tuberculosis, and efforts to develop new therapie

44 y care improved identification of active and latent tuberculosis, and increased BCG coverage.

45 imilar among healthy controls, patients with latent tuberculosis, and patients with active tuberculos

46 n immunodeficiency virus (HIV) infection and latent tuberculosis are at substantial risk for the deve

47 he mechanisms involved in the containment of latent tuberculosis are poorly understood.

48 s unlikely that a country detects and treats latent tuberculosis at a high enough rate to justify the

49 By contrast, screening for latent tuberculosis before immune checkpoint inhibitor t

50 unted for 1.2% (95% UI 1.0-1.4) of the total latent tuberculosis burden overall, but for 2.9% (95% UI

51 viously described with isoniazid therapy for latent tuberculosis but resulted in a high completion ra

52 c population isoniazid is a safe therapy for latent tuberculosis, but its effectiveness is limited by

53 own a high yield of tuberculosis disease and latent tuberculosis, but the yield of such investigation

54 street-level pollution decreased the odds of latent tuberculosis by 36% (adjusted odds ratio, 0.64; 9

55 rted data on migrant screening for active or latent tuberculosis by any method before migration to a

56 f current trends continue, the proportion of latent tuberculosis caused by MDR strains will increase,

57 All standard treatments for latent tuberculosis contain drugs to which multidrug-res

58 Reactivation of latent tuberculosis contributes significantly to the inc

59 would identify individuals at high risk for latent tuberculosis despite negative test results.

60 cidence included substance or alcohol abuse, latent tuberculosis, diabetes mellitus, atypical mycobac

61 In this study, treatment of latent tuberculosis during transplant candidacy period i

62 en experienced a 2.56-fold increased odds of latent tuberculosis for each additional household member

63 es identified in all migrant groups included latent tuberculosis, found in 43% of migrants, eosinophi

64 /microL) and HIV-uninfected individuals with latent tuberculosis from South Africa.

65 Individuals with latent tuberculosis had 79% lower risk of progressive tu

66 Mass screening and treatment for latent tuberculosis had no significant effect on tubercu

67 Latent tuberculosis has been recognized for over a centu

68 nce between commercially available tests for latent tuberculosis in a low-prevalence population, incl

69 setting of TNF neutralization in primary and latent tuberculosis in a non-human primate model.

70 , our results suggest that the prevalence of latent tuberculosis in China might be overestimated by s

71 hese monkeys had clinical characteristics of latent tuberculosis in humans.

72 Treatment of latent tuberculosis in liver transplant patients during

73 QuantiFERON-TB Gold test (QFT-GT) to detect latent tuberculosis in newly hired health care workers w

74 n a dormant state and may be responsible for latent tuberculosis in one-third of the world's populati

75 Treatment of latent tuberculosis in patients infected with the human

76 The Q-G test cannot detect latent tuberculosis in patients with leprosy.

77 berculosis; (4) the management of active and latent tuberculosis in pregnancy and the postpartum peri

78 We discuss the diagnosis of latent tuberculosis in SOT candidates/recipients using t

79 tic aerosol infection model or in a model of latent tuberculosis in the lungs.

80 ornell model is a historical murine model of latent tuberculosis, in which mice infected with M. tube

81 n DC had a similar prevalence as refugees of latent tuberculosis infection (39% vs 38%, respectively,

82 ling approach, we show that individuals with latent tuberculosis infection (Ltb) and active tuberculo

83 dence of tuberculosis among individuals with latent tuberculosis infection (LTBI group) and without l

84 Predictors of latent tuberculosis infection (LTBI) among close contact

85 We compared the prevalence of latent tuberculosis infection (LTBI) among persons who h

86 e used to evaluate new interventions against latent tuberculosis infection (LTBI) and predict reactiv

87 Persons at high risk of latent tuberculosis infection (LTBI) and/or progression

88 Pregnant women with latent tuberculosis infection (LTBI) are at high risk fo

89 Immunocompromised persons with latent tuberculosis infection (LTBI) are at increased ri

90 Renal transplant candidates (RTC) with latent tuberculosis infection (LTBI) are at significant

91 nale: Noninferiority trials of treatment for latent tuberculosis infection (LTBI) are challenging bec

92 The tests for diagnosing latent tuberculosis infection (LTBI) are limited by a po

93 Contacts with latent tuberculosis infection (LTBI) are offered chemopr

94 s behind TB reactivation in individuals with latent tuberculosis infection (LTBI) coinfected with HIV

95 Most cases of latent tuberculosis infection (LTBI) do not cause sympto

96 Current guidelines limit latent tuberculosis infection (LTBI) evaluation to perso

97 iew guidance on the testing and treatment of latent tuberculosis infection (LTBI) in children.

98 erium tuberculosis (Mtb) during asymptomatic latent tuberculosis infection (LTBI) in humans is curren

99 release assays (IGRAs) for the diagnosis of latent tuberculosis infection (LTBI) in individuals with

100 The prevalence and incidence of latent tuberculosis infection (LTBI) in patients with ki

101 ates of noncompletion of treatment (NCT) for latent tuberculosis infection (LTBI) in the PREVENT TB t

102 The scope of treatment of latent tuberculosis infection (LTBI) in the United State

103 Targeted testing and treatment (TTT) for latent tuberculosis infection (LTBI) is a recommended st

104 Effective treatment of latent tuberculosis infection (LTBI) is an important com

105 Treatment of latent tuberculosis infection (LTBI) is an important com

106 an association between cigarette smoking and latent tuberculosis infection (LTBI) is based on studies

107 Identifying persons with latent tuberculosis infection (LTBI) is crucial to the g

108 Treatment of latent tuberculosis infection (LTBI) is important for tu

109 While this latent tuberculosis infection (LTBI) is not contagious,

110 Screening and therapy of latent tuberculosis infection (LTBI) is recommended in s

111 Individuals with latent tuberculosis infection (LTBI) live with a risk of

112 ific inflammatory responses used to identify latent tuberculosis infection (LTBI) lose positivity dur

113 Identification and treatment of latent tuberculosis infection (LTBI) mitigate the risk o

114 The increased susceptibility to latent tuberculosis infection (LTBI) of HIV-1-infected p

115 tuberculosis before entry to the UK and for latent tuberculosis infection (LTBI) post-entry for redu

116 Five to ten percent of individuals with latent tuberculosis infection (LTBI) progress to active

117 Efforts to expand treatment of latent tuberculosis infection (LTBI) raise concerns for

118 ccurate detection and risk stratification of latent tuberculosis infection (LTBI) remains a major cli

119 ence of the association between diabetes and latent tuberculosis infection (LTBI) remains limited and

120 Latent tuberculosis infection (LTBI) screening and treat

121 e assay (IGRA) is costly and not included as latent tuberculosis infection (LTBI) screening test stra

122 In latent tuberculosis infection (LTBI) spread of the bacte

123 Latent tuberculosis infection (LTBI) test discordance is

124 ease and for predicting the progression from latent tuberculosis infection (LTBI) to ATB.

125 sease is the identification and treatment of latent tuberculosis infection (LTBI) to prevent progress

126 Increased risk of progression from latent tuberculosis infection (LTBI) to tuberculosis (TB

127 ha therapy is associated with progression of latent tuberculosis infection (LTBI) to tuberculosis (TB

128 HCW acceptance and compliance with available latent tuberculosis infection (LTBI) treatment regimens

129 tion, and adverse events associated with all latent tuberculosis infection (LTBI) treatments, there i

130 Among SIV adults, 14.4% were diagnosed with latent tuberculosis infection (LTBI), 63.5% were suscept

131 ly one-quarter of the global population have latent tuberculosis infection (LTBI), and tuberculosis (

132 ped with the aim to improve the detection of latent tuberculosis infection (LTBI), especially among r

133 ce of a scar or vaccination history, against latent tuberculosis infection (LTBI), measured via IGRA,

134 known to influence T and B cell responses in latent tuberculosis infection (LTBI).

135 ccines and to screen health care workers for latent tuberculosis infection (LTBI).

136 ients, are at increased risk of reactivating latent tuberculosis infection (LTBI).

137 ) is recommended by the CDC for treatment of latent tuberculosis infection (LTBI).

138 blood-based tests intended for diagnosis of latent tuberculosis infection (LTBI).

139 We assessed the prevalence of latent tuberculosis infection (tuberculin skin test reac

140 or may have no clinical evidence of disease (latent tuberculosis infection [LTBI]).

141 Latent tuberculosis infection affects one third of the w

142 Fluoroquinolone (FQN) therapy of latent tuberculosis infection among contacts of individu

143 be implemented that identified persons with latent tuberculosis infection among jail inmates and pro

144 lack the specificity to distinguish between latent tuberculosis infection and active tuberculosis.

145 T for identification of individuals who have latent tuberculosis infection and could improve tubercul

146 We estimated the prevalence of latent tuberculosis infection at baseline and examined t

147 lomic profiles compared to those who develop latent tuberculosis infection but prior to any signs of

148 Liver transplant candidates with latent tuberculosis infection by positive tuberculin ski

149 1,128 children who were all investigated for latent tuberculosis infection by tuberculin skin test an

150 on mRNA biogenesis pathways are repressed in latent tuberculosis infection compared with cured diseas

151 Among persons with latent tuberculosis infection detected during screening

152 demonstrate how effective therapy for early latent tuberculosis infection has to be to eliminate tub

153 elling underline the necessity of addressing latent tuberculosis infection if further progress is to

154 yrazinamide are recommended for treatment of latent tuberculosis infection in adults without HIV infe

155 r progress, scale-up of targeted testing for latent tuberculosis infection in at-risk populations, sc

156 urces were associated with increased odds of latent tuberculosis infection in child household contact

157 scuss the importance of strategies to target latent tuberculosis infection in high risk populations a

158 ive as daily isoniazid for 9 months (9H) for latent tuberculosis infection in high-risk persons, but

159 useful for evaluation of new treatments for latent tuberculosis infection in humans.

160 Mycobacterium tuberculosis (Mtb) causes latent tuberculosis infection in one-third of the world

161 more sensitive than the TST for diagnosis of latent tuberculosis infection in patients on hemodialysi

162 ntify the effectiveness of therapy for early latent tuberculosis infection in reducing the prevalence

163 ard 9-month INH regimen for the treatment of latent tuberculosis infection in solid-organ transplant

164 ostic accuracy of these tests in determining latent tuberculosis infection in the hemodialysis popula

165 -G, and TSPOT.TB with regards to determining latent tuberculosis infection in the hemodialysis popula

166 e to that of the presumed background rate of latent tuberculosis infection in the state of Alabama.

167 ce-weekly isoniazid and rifapentine to treat latent tuberculosis infection in the United States, and

168 An alternative regimen for the treatment of latent tuberculosis infection is 2 months of rifampin an

169 active tuberculosis through the treatment of latent tuberculosis infection is a major element of the

170 f rifapentine and isoniazid for treatment of latent tuberculosis infection is safe and effective for

171 ronchoalveolar lavage cells from donors with latent tuberculosis infection limited the growth of viru

172 The rifampin/pyrazinamide regimen for latent tuberculosis infection may be useful for high-ris

173 To end the global tuberculosis epidemic, latent tuberculosis infection needs to be addressed.

174 drug, physicians should screen patients for latent tuberculosis infection or disease.

175 ated with one of three standard regimens for latent tuberculosis infection or tumor necrosis factor (

176 The extent to which latent tuberculosis infection reduces the risk of progre

177 tulating the sterilizing activities of human latent tuberculosis infection regimens.

178 The diagnosis of latent tuberculosis infection relies on the tuberculin s

179 munodeficiency virus-induced reactivation of latent tuberculosis infection results in an increased ex

180 The billions of people with latent tuberculosis infection serve as the seedbeds for

181 Expanded testing and treatment for latent tuberculosis infection to all HIV-infected adults

182 ate the global burden of multidrug-resistant latent tuberculosis infection to inform tuberculosis eli

183 indicate reactivation risk, and even shorter latent tuberculosis infection treatment regimens than cu

184 ious periods, and clinicians should consider latent tuberculosis infection treatment-tailored to the

185 y searched for and included studies in which latent tuberculosis infection was assessed in 2 groups:

186 A strategy of detecting and treating latent tuberculosis infection was cost-saving among immi

187 Latent tuberculosis infection was found in 577 of 878 (6

188 Latent tuberculosis infection was measured through tuber

189 ng antiretroviral therapy; participants with latent tuberculosis infection were eligible if they had

190 Rates of latent tuberculosis infection were higher for men than w

191 ng tuberculosis from other diseases and from latent tuberculosis infection were identified from genom

192 s of the tuberculin skin test and those with latent tuberculosis infection were offered IPT.

193 e detected in three healthy individuals with latent tuberculosis infection who also had strong anti-M

194 ately distinguished active tuberculosis from latent tuberculosis infection with an area under the cur

195 Treatment of latent tuberculosis infection with isoniazid (INH) or ri

196 ations, a strategy of detecting and treating latent tuberculosis infection would lead to substantial

197 itis B, and 133 [51%] of 263 individuals for latent tuberculosis infection), mental health (eg, highe

198 cells and the ability to control infection (latent tuberculosis infection, 62%; posttuberculosis pat

199 r memory phenotype in active tuberculosis vs latent tuberculosis infection, accompanied by a reductio

200 disease can be missed during evaluations for latent tuberculosis infection, and can manifest with sym

201 In China, the prevalence of latent tuberculosis infection, and preventive interventi

202 of active tuberculosis, the reactivation of latent tuberculosis infection, and the induction of prot

203 persons with greatest need for treatment of latent tuberculosis infection, as new shorter and less t

204 Given the estimated prevalence of latent tuberculosis infection, compared with the limited

205 cy, including: (1) preventing progression of latent tuberculosis infection, especially in women coinf

206 Asylees had higher prevalence of latent tuberculosis infection, hepatitis B and HIV serop

207 s potential applications in the diagnosis of latent tuberculosis infection, in monitoring response to

208 uberculosis for experimental chemotherapy of latent tuberculosis infection, mice were immunized with

209 During human latent tuberculosis infection, Mycobacterium tuberculosi

210 recommendations about diagnostic testing for latent tuberculosis infection, pulmonary tuberculosis, a

211 Standard assessments of interaction between latent tuberculosis infection, the HIV serostatus of ind

212 ts with anergy and multiple risk factors for latent tuberculosis infection, the rate of development o

213 ity in subjects with active tuberculosis and latent tuberculosis infection, with and without human im

214 l growth associated with stress survival and latent tuberculosis infection, yet the activities and in

215 herapy in 17 consecutive SOT candidates with latent tuberculosis infection.

216 ulosis, diseases other than tuberculosis, or latent tuberculosis infection.

217 berculin skin testing (TST) for diagnosis of latent tuberculosis infection.

218 alpha were greater in active tuberculosis vs latent tuberculosis infection.

219 scrimination between active tuberculosis and latent tuberculosis infection.

220 w to interpret discordance between tests for latent tuberculosis infection.

221 l blood mononuclear cells from subjects with latent tuberculosis infection.

222 ampered by the absence of a perfect test for latent tuberculosis infection.

223 ction and is a validated drug target against latent tuberculosis infection.

224 servoir of persistent organisms during human latent tuberculosis infection.

225 k should be directed toward the treatment of latent tuberculosis infection.

226 ure of the population, and the prevalence of latent tuberculosis infection.

227 oost the immune response of individuals with latent tuberculosis infection.

228 ng therapy to persons with recently acquired latent tuberculosis infection.

229 trials of interventions to prevent or treat latent tuberculosis infection.

230 acterium tuberculosis complex bacilli during latent tuberculosis infection.

231 ing persistent state of this pathogen during latent tuberculosis infection.

232 berculosis prevalence or who had evidence of latent tuberculosis infection.

233 associated with increased susceptibility to latent tuberculosis infection.

234 duced T-cell responses and susceptibility to latent tuberculosis infection.

235 ed >/=18 years) recommended for treatment of latent tuberculosis infection.

236 gs and lung granulomas of animals exhibiting latent tuberculosis infection.

237 17 years) who were eligible for treatment of latent tuberculosis infection.

238 short-course rifapentine-based regimens for latent tuberculosis infection.Methods: Rifapentine pharm

239 plicated the choice of treatment regimen for latent tuberculosis infection.Objectives: To evaluate th

240 tests available to determine the presence of latent tuberculosis infection: the tuberculin skin test

241 culosis (ATB) from healthy controls (HC) and latent tuberculosis infections (LTBI).

242 is, and screening and preventive therapy for latent tuberculosis infections in individuals with diabe

243 on is thought to be involved in establishing latent tuberculosis infections in response to hypoxia an

244 or in combination with rifapentine to treat latent tuberculosis infections.

245 ch may explain why isoniazid monotherapy for latent tuberculosis is a risk factor for the emergence o

246 ial to the etiology of Tuberculosis, because latent tuberculosis is estimated to affect one-third of

247 A major risk factor for reactivation of latent tuberculosis is HIV infection, suggesting a role

248 es, its effect on the protective response to latent tuberculosis is not known.

249 ir role in modulating chemokine responses in latent tuberculosis (LTB) has not been explored.

250 are known to modulate cytokine responses in latent tuberculosis (LTB).

251 dations for treating persons having presumed latent tuberculosis (LTBI) after contact to infectious m

252 idance on the optimal screening strategy for latent tuberculosis (LTBI) in patients about to start an

253 led trials have demonstrated that the newest latent tuberculosis (LTBI) regimen, 12 weekly doses of d

254 prevent reactivation of disease in a murine latent-tuberculosis model.

255 ared gene expression in patients with either latent tuberculosis or other diseases versus patients wi

256 01), behcet's disease (p = 0.0001), presumed latent tuberculosis (p = 0.0001), presumed latent syphil

257 01), behcet's disease, (p = 0.0001) presumed latent tuberculosis (p = 0.001), presumed latent syphili

258 et's disease, presumed sarcoidosis, presumed latent tuberculosis, presumed latent syphilis, and contr

259 We fit the model to local data on latent tuberculosis prevalence by age.

260 Studies have shown that shorter latent tuberculosis prevention regimens containing rifam

261 e infection with M. tuberculosis and contain latent tuberculosis, providing a rationale for the clini

262 ent used to aid diagnosis of both active and latent tuberculosis, purified protein derivative (PPD),

263 Latent tuberculosis represents a high-risk burden for on

264 t of nonreplicating persistence, and thereby latent tuberculosis, resisted extensive attempts at crys

265 Given the impact of latent Tuberculosis, RpfB represents an interesting targ

266 n test (TST) to IFN-gamma release assays for latent tuberculosis screening are reporting challenges w

267 e assay (QFT) is increasingly being used for latent tuberculosis screening in patients infected with

268 California data demonstrate failures in latent tuberculosis screening to prevent progression to

269 during latency, and experimental studies on latent tuberculosis suffer from a lack of appropriate an

270 Identifying and treating persons with latent tuberculosis (TB) infection (LTBI) at high risk f

271 Treatment of latent tuberculosis (TB) infection (LTBI) is essential f

272 a) therapy is associated with progression of latent tuberculosis (TB) infection (LTBI) to TB disease,

273 critical risk factor for the reactivation of latent tuberculosis (TB) infection (LTBI).

274 The role of genetic polymorphisms in latent tuberculosis (TB) infection and progression to ac

275 Isoniazid preventive therapy for latent tuberculosis (TB) infection has been debated beca

276 eveloping improved regimens for treatment of latent tuberculosis (TB) infection include (1) developin

277 between August 1, 2010 and July 31, 2011 for latent tuberculosis (TB) infection screening with an IGR

278 During human latent tuberculosis (TB) infection, dormant bacilli puta

279 t M. tuberculosis (D-Mtb) is responsible for latent tuberculosis (TB) infection.

280 modifying its physiology and establishing a latent tuberculosis (TB) infection.

281 Differentiation of active from latent tuberculosis (TB) is a major challenge in the con

282 ew IFN-gamma release assays for diagnosis of latent tuberculosis (TB), but also provided evidence tha

283 rial infection, particularly of reactivating latent tuberculosis (TB).

284 hout causing disease, in a syndrome known as latent tuberculosis (TB).

285 We evaluated three new regimens for latent tuberculosis that may be more potent and durable

286 Among Inf subjects with definitive latent tuberculosis, there were no differences in freque

287 blished prior to the widespread treatment of latent tuberculosis to estimate the incidence of tubercu

288 ion from previous estimates of the burden of latent tuberculosis to generate trends in the annual ris

289 tis B virus and hepatitis C virus status and latent tuberculosis], to assess the risk of adverse even

290 We extracted information from our latent tuberculosis treatment database to determine adve

291 s chapter provides an overview of active and latent tuberculosis treatment in HIV-infected and -uninf

292 as new shorter and less toxic regimens make latent tuberculosis treatment in older adults more attra

293 Expanding latent tuberculosis treatment is important to decrease a

294 ction, and can manifest with symptoms during latent tuberculosis treatment.

295 erculosis infection (LTBI group) and without latent tuberculosis (uninfected; UI group).

296 Among over 8000 patients treated for latent tuberculosis we found no evidence of acquired dru

297 al-therapy-naive, HIV-1-infected adults with latent tuberculosis, we identified ten individuals with

298 to persist is key for finding ways to limit latent tuberculosis, which affects one-third of the worl

299 ation of a robust immune response leading to latent tuberculosis, which is regarded as a spectrum rat

300 Screening for latent tuberculosis with tuberculin skin testing is effe